nav-left cat-right
cat-right

Source BioScience, DNAFORM to Offer Japanese Versi...

Source BioScience and DNAFORM are launching the Japanese version of Source BioScience’s GenomeCube® database and webstore. GenomeCube provides access to a portfolio of 20 million DNA clones and antibodies for research purposes. With the launch of the Japanese version, local research scientists will be able to access DNA clones representing nearly every known human and mouse gene in addition to many genes from...

Beckman Coulter to Start Sequencing Clinical Sampl...

Beckman Coulter reports that it will begin accepting clinical samples for genetic sequencing. The company has obtained a CLIA certificate of registration along with Massachusetts State Licensure. This certification paves the way for detection of BRAF exon 11 (codons 439–477) and exon 15 (codons 581–620) for mutations using PCR-based DNA sanger sequencing, the first clinical molecular diagnostic assay the...

Pancreatic Cancer Target Identified that Protects ...

Scientists have identified a potential pancreatic cancer target that in a mouse model appears to play an essential role in tumorigenesis, and in human patients correlates with poor survival. Nuclear protein 1 (Nupr1) mediates stress response in the pancreas and is often upregulated in pancreatic cancer. In vitro and in vivo studies by a Centre de Recherche en Cancérologie de Marseille (CRCM)-led team showed that Nupr1...

ArcDia Raises €2.7M for Multianalyte Respiratory I...

ArcDia raised €2.7 million (about $3.5 million) in an investment round to expand its mariPOC® diagnostic system. The point-of-care platform simultaneously tests for nine common viruses and bacteria responsible for respiratory tract infections using a single nasopharyngeal or throat swab, or sample of aspirate. Pathogens detected include influenza A/B, respiratory syncitial virus, and parainfluenza viruses 1, 2, and...

Celgene Pays Epizyme $90M for Ex-U.S. Rights to Hi...

Celgene is paying Epizyme $90 million up front to established a partnership focused on the discovery, development, and commercialization of histone methyltransferase (HMT)-inhibiting drugs for genetically defined cancers. The up-front fee includes an equity investment in Epizyme and gives Celgene exclusive immediate ex-U.S. rights to its partner’s existing DOT1L HMT inhibitor program against mixed lineage leukemia...

RiboMed Launches Improved Prognostic Multi Biomark...

RiboMed Clinical Services Laboratory (RCSL), a CLIA-certified subsidiary of RiboMed Biotechnologies, today announced the release of a multi-marker methylation prognostic test for grading gliomas, the most common type of brain cancer. The test robustly analyzes 8 genes for differential methylation on FFPE (Formalin Fixed Paraffin Embedded) tumor samples to determine the G-CIMP (Glioma CpG Island Methylation Phenotype) score....
Page 5 of 11« First...34567...10...Last »